Pub Med recently conducted a survey, asking for opinions about the use of medical marijuana and cannabidiol (CBD) for people with epilepsy. The survey consisted of eight questions. Four questions asked if ‘there were sufficient safety and efficacy data, whether responders would advise trying medical marijuana in cases of severe refractory epilepsy, and if pharmacologic grade compounds containing CBD should be available.’ Of the 776 people who started or completed the survey, 58% were patients from North America, and 22% were epileptologists and general neurologists from Europe and North America. The survey found the following:
- Nearly all patients and the public said there were sufficient safety (96%) and efficacy (95%) data, and 98% would recommend medical marijuana in cases of severe epilepsy.
- General physicians, basic researchers, nurses, and allied health professions sided more with patients, saying that there were sufficient safety (70%) and efficacy (71%) data, and 83% would advise using marijuana in severe cases.
- A majority (78%) said there should be pharmacologic grade compounds containing CBD, and there were no differences between specialists, general medical personal, and patients and the public.
Unfortunately the survey found that a minority of specialists said that there were sufficient safety (34%) and efficacy (28%) data, and 48% would advise using medical marijuana in severe cases of epilepsy. Hopefully more specialists do their homework and see that not only is their opinion not in line with the public, patients, general physicians, basic researchers, nurses, and allied health professionals, but that CBD is a great medicine for patients that suffer from epilepsy. As more research is conducted, I’m confident that the results will be undeniably in favor of CBD.